Beckley Psytech strengthens its management team with the appointment of Dr. Laura Trespidi as Director of Development
OXFORD, England–(BUSINESS WIRE)–Beckley Psytech, a private company dedicated to treating neurological and psychiatric disorders through the innovative application of psychedelic drugs, today announced the appointment of Dr. Laura Trespidi as Chief Development Officer.
Dr. Trespidi brings over 30 years of experience in global pharmaceutical and biotechnology companies, developing and manufacturing clinical products, from preclinical research to market approvals and global product launches. Most recently, as Senior Vice President, Chemistry, Manufacturing and Controls (CMC), Supply Chain and Technical Operations at Summit Therapeutics, Dr. Trespidi successfully led global CMC and external manufacturing teams throughout development and market readiness of investigational drugs, including end-of-end supply chain and manufacturing readiness and expansion.
Dr. Trespidi’s expertise extends to formulation development, technology transfers, outsourcing and offshoring, with additional experience in developing and executing change management strategies. Throughout her career, Dr. Trespidi has played a pivotal role in more than 40 first-in-man clinical and preclinical trials, in addition to contributing to four New Drug Applications (NDAs) and marketing approvals, and more than 40 experimental new drugs. (IND).
The world-class leadership and technical expertise acquired at Summit Therapeutics and other leading companies such as Mundipharma, Shire Pharmaceuticals and GlaxoSmithKline, will enable Dr. Trespidi to support the progression and development of Beckley Psytech’s investigational assets, including proprietary formulations of 5-MeO-DMT, currently in phase 1 studies.
Dr. Trespidi obtained his doctorate. in Pharmaceutical Sciences from the University of Milan, Italy; an M.Sc. in Medicinal Chemistry and Biochemistry from the University of North Carolina, USA; and in 2008 she obtained an MBA from the Open University Business School, UK. Dr. Trespidi is the author of a number of articles published in peer-reviewed journals and is a member of several scientific societies and associations.
Cosmo Feilding Mellen, CEO of Beckley Psytech, said: “Dr. Trespidi joins us as Chief Development Officer at an exciting time, with our lead drug candidates in Phase 1 clinical studies. Laura’s impressive track record and expertise in clinical development and manufacturing will be invaluable as Beckley Psytech continues to grow and advance its clinical pipeline in this revolutionary area of medicine.
Dr. Laura Trespidi, CDO of Beckley Psytech, said: “I am thrilled to join Beckley Psytech at such a transformative time for society and for psychedelic medicines. Beckley Psytech’s innovative pipeline has real potential to deliver meaningful improvement to patients’ lives, and I look forward to working on alongside a world-class team to turn this vision into reality.
Beckley Psytech – www.beckleypsytech.com
Beckley Psytech is a private, clinical-stage company dedicated to helping patients with neurological and psychiatric disorders by developing a wide range of psychedelic compounds in rare and more common diseases. Our vision is to integrate clinically validated psychedelic drugs into modern medical practice to help patients with high unmet medical needs worldwide suffering from treatment-resistant depression and other profoundly debilitating neurological conditions. Beckley Psytech was founded in 2019 drawing on some of the expertise developed over more than 20 years by the Beckley Foundation, an independent, not-for-profit global leader in psychedelic medicine research, and is based in Oxford. , UK.